# Tenaya Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tenaya-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.tenayatherapeutics.com
- Total disclosed funding: $167M
- Latest round: Series C (Dec 17, 2020)
- Investors on record: 8

## About

Based in California, US, and founded in 2016, Tenaya Therapeutics, Inc. operates as a biopharmaceutical company that utilizes regeneration, gene therapy, and precision medicine platforms in developing therapies for the treatment of heart diseases. The company has 85 employees as of May 2021 and was co-founded by Deepak Srivastava, M.D., Eric Olson, Ph.D., Bruce R. Conklin, M.D., Sheng Ding, Ph.D., Saptarsi Haldar, M.D., and Benoit G. Bruneau, Ph.D. Faraz Ali is the CEO of the company as of August 2021. In July 2021, Tenaya Therapeutics raised USD 180 million in an IPO, selling 12 million shares at USD 15 per share on the Nasdaq.

The company's line of products includes a regeneration platform that focuses on developing a treatment for cardiomyocytes and cardiac fibroblasts. The Gene therapy platform focuses on the treatment of genetic hypertrophic cardiomyopathy (HCM). And a precision medicine platform that focuses on developing a small molecule therapy against an unnamed target and has demonstrated compelling in vivo efficacy in a model for genetic dilated cardiomyopathy (DCM).

Tenaya Therapeutics plans to accelerate the pipeline of potentially curative therapies for heart disease.

## Funding rounds

- Series C, Dec 17, 2020, $86M — T Rowe Price, The Column Group, Fidelity Investments, GV, Casdin Capital, RTW Investments, RA Capital Management
- Series B, Oct 3, 2019, $31M — Greenspring Associates, The Column Group, GV, Casdin Capital
- Series A, Dec 6, 2016, $50M — The Column Group

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C